Eusa Pharma Divests Antibody Research Business
Posted on: Friday, 2 May 2008, 09:01 CDT
Eusa Pharma has divested its monoclonal antibody research business to the French company International Drug Development.
Concurrently, Eusa has divested its recombinant L-asparaginase therapeutic research program for acute lymphoblastic leukemia to the Alize Pharma Group. EUSA acquired both the antibody business and oncology program as part of its 2007 acquisition of OPi.
Eusa's antibody research business is based in Dardilly, France, and consists of a team of R&D scientists, laboratories and a library of approximately 600 murine antibodies, of which a high proportion are currently characterized.
The divestment agreement for Eusa's recombinant L-asparaginase therapeutic research program includes an option for the company to license back any resulting product. This provides Eusa with access to a potential future product that has an ideal fit with the company's oncology focus.
Source: Datamonitor
Related Articles
- Oncolin's Research Program Receives NIH Grant
- Accelr8 Announces Research Programs in Two Leading Medical Research Centers
- Chevron and MIT Announce Energy Research Program
- University Coal Research Program Begins
- Advanced Cell Applauds $3 Billion Stem Cell Research Program, Proposition 71, Upheld Monday By A California Appeals Court
- Iran insists on nuclear fuel research program
- Stem-Cell Research Program Sought
- Medivir: Advances in Chronic Obstructive Pulmonary Disease (COPD) Research Program
- St. Louis Airport Director Appointed to Airport Cooperative Research Program Board
 |
 |
User Comments (0)
RSS Feeds